A team of high school journalists on what's working — and what isn't — with Oregon's new ban on cell phones in schools.

A promising breakthrough in autoimmune disease research may open the door to safer and more effective treatments. Scientists ...

As flu season approaches and public health officials roll out their annual push for vaccination, Allen Institute scientists ...

Caribou Biosciences, Inc. recently reported very exciting early data, with more in the allogeneic CAR T-cell pipeline. Read ...

Chimeric antigen receptor T-cell therapy has exhibited “compelling” efficacy and safety in lupus, allowing 84% of patients to ...

BMY's growth-driving portfolio increased 17% year-over-year, prompting an upward revision in 2025 revenue guidance and ...

“Utilizing real-world data, technology, strategic solutions, and cross-departmental partnerships will help ensure equitable access, so the right member receives the right drug at the right time and ...

Molecular analysis identified ABC and GCB subtypes, with the ABC subtype benefiting more from the new regimen. The identification of biomarkers in frontline diffuse large B-cell lymphoma (DLBCL) is ...

Data demonstrate efficacy and durability of vispa-cel, an allogeneic anti-CD19 CAR-T cell therapy, are on par with autologous CAR-T cell therapies in the confirmatory cohort (N=22) and with ...

Oral presentation of GLPG5101 data from the ATALANTA-1 study in patients with high-risk relapsed/refractory mantle cell lymphoma ...

Discover how CAR T cell therapy is breaking new ground in treating Multiple Sclerosis for the first time in the UK ...